Literature DB >> 21404317

PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.

Randall K Leong1, Stefan G G De Wachter, F H M Nieman, Rob A de Bie, Philip E V van Kerrebroeck.   

Abstract

AIMS: To compare the patient's response rate to the Percutaneous Nerve Evaluation test (PNE) and the 1st stage tined-lead placement test (FSTLP) for sacral neuromodulation therapy (SNM).
METHODS: Single center study on patients with refractory idiopathic overactive bladder syndrome (OAB) or non-obstructive urinary retention, screened with both PNE and FSTLP. Patients were followed prospectively and their response rate based on bladder diary after PNE was compared to that after FSTLP. More than 50% improvement in at least two relevant urinary symptoms was considered a positive response. A Wilcoxon paired test was done to compare the rates of the two screening options and logistic regression to determine possible associations. A follow-up was conducted to determine the long-term failure rate.
RESULTS: One hundred patients were included (82 female, 69 OAB). The mean age was 55 years (SD 13). The positive response rate on PNE was 47%. FSTLP showed a 69% positive response rate, which was negatively related to age. The 22% gain in positive response was statistically significant (P < 0.001) and positively associated with female gender and younger age. All 69 patients with a positive response to FSTLP received SNM treatment. Failure rate after an average of 2 years was 2.9%.
CONCLUSIONS: This study suggests that FSTLP may be a more sensitive screening method than PNE to identify patients eligible for SNM therapy, warranting randomized trials.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21404317     DOI: 10.1002/nau.20979

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  13 in total

Review 1.  How does sacral modulation work best? Placement and programming techniques to maximize efficacy.

Authors:  Bastian Amend; Mahmoud Khalil; Thomas M Kessler; Karl-Dietrich Sievert
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

Review 2.  Percutaneous tibial nerve stimulation and sacral neuromodulation: an update.

Authors:  Priyanka Gupta; Michael J Ehlert; Larry T Sirls; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

Review 3.  Where Are We Headed with Neuromodulation for Overactive Bladder?

Authors:  Kaitlin Jaqua; Charles R Powell
Journal:  Curr Urol Rep       Date:  2017-08       Impact factor: 3.092

4.  Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.

Authors:  Maria Paola Bertapelle; Mario Vottero; Giulio Del Popolo; Marco Mencarini; Edoardo Ostardo; Michele Spinelli; Antonella Giannantoni; Anna D'Ausilio
Journal:  World J Urol       Date:  2014-09-14       Impact factor: 4.226

Review 5.  Understanding clinic options for overactive bladder.

Authors:  Jamie M Bartley; Emily S Blum; Larry T Sirls; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 6.  Neuromodulation for overactive bladder.

Authors:  Jamie Bartley; Jason Gilleran; Kenneth Peters
Journal:  Nat Rev Urol       Date:  2013-07-02       Impact factor: 14.432

7.  Predictive Factors in Sacral Neuromodulation: A Systematic Review.

Authors:  Ranjana Jairam; Jamie Drossaerts; Tom Marcelissen; Gommert van Koeveringe; Desiree Vrijens; Philip van Kerrebroeck
Journal:  Urol Int       Date:  2021-05-31       Impact factor: 1.934

Review 8.  Overactive bladder - 18 years - Part II.

Authors:  Jose Carlos Truzzi; Cristiano Mendes Gomes; Carlos A Bezerra; Ivan Mauricio Plata; Jose Campos; Gustavo Luis Garrido; Fernando G Almeida; Marcio Augusto Averbeck; Alexandre Fornari; Anibal Salazar; Arturo Dell'Oro; Caio Cintra; Carlos Alberto Ricetto Sacomani; Juan Pablo Tapia; Eduardo Brambila; Emilio Miguel Longo; Flavio Trigo Rocha; Francisco Coutinho; Gabriel Favre; Jose Antonio Garcia; Juan Castano; Miguel Reyes; Rodrigo Eugenio Leyton; Ruiter Silva Ferreira; Sergio Duran; Vanda Lopez; Ricardo Reges
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

9.  Predictors of implantable pulse generator placement after sacral neuromodulation: who does better?

Authors:  Jennifer T Anger; Anne P Cameron; Rodger Madison; Christopher Saigal; J Quentin Clemens
Journal:  Neuromodulation       Date:  2013-09-18

10.  Outcomes of Sacral Neuromodulation in a Privately Insured Population.

Authors:  Jennifer T Anger; Anne P Cameron; Rodger Madison; Christopher Saigal; J Quentin Clemens
Journal:  Neuromodulation       Date:  2016-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.